Cytokinetics, Incorporated (CYTK) Earnings Call Transcript & Summary
March 3, 2020
Earnings Call Speaker Segments
Diane Weiser
executiveGood afternoon, and thank you for being with us on today's call. Robert Blum, who serves as our President and Chief Executive Officer, is going to start things off by highlighting the main achievements from 2019 and walking through our Vision 2025. Fady Malik, our EVP of Research and Development, will share updates on important progress for omecamtiv mecarbil, which is our cardiac myosin activator, as well as AMG 594, our cardiac troponin activator — both of these fall under the collaboration we have with Amgen. Fady will also report on recent advances with CK-274, a wholly owned cardiac myosin inhibitor of ours that is now in phase II, and CK-271, our other cardiac myosin inhibitor. Andy Wolff, who has been our Chief Medical Officer for the past 15 years and is now Senior Fellow, Clinical Research and Development, will give a brief update concerning reldesemtiv, our fast skeletal muscle troponin activator. Robert Wong, our VP and Chief Accounting Officer, will follow with a financial overview covering the quarter, and Ching Jaw, our SVP and Chief Financial Officer, will talk about corporate development strategies along with financial guidance, after which Robert Blum will offer concluding thoughts regarding the company's outlook and the key milestones we expect for the year. Lastly, Stuart Kupfer, who was recently appointed as our Chief Medical Officer, is also with us today and will be delivering clinical research updates on upcoming calls. Please be aware that parts of the discussion that follows, including how we respond to questions, include statements pertaining to future events and performance instead of historical facts, and these constitute forward-looking statements. Results we actually achieve could differ materially from what those forward-looking statements project. Further details about factors that might cause our actual results to diverge materially from those in these forward-looking statements can be found in our SEC filings. We assume no obligation to update any forward-looking statements following this call. Now, I'll hand the call over to Robert.
Robert Blum
executiveI appreciate that, Diane, and once more, I want to thank everybody for being on today's call. 2019 brought robust results and dependable progress on the objectives we set. Four drug candidates are now moving forward in clinical development, and one more is ready to enter the clinic during this year, so we're in a strong spot to achieve our Vision 2025. That vision sees us becoming the top biopharmaceutical company centered on muscle biology, one that finds, creates, and brings to market novel treatments that could significantly better the lives of people dealing with weakened muscle function and diseases of impaired muscle. Not long ago we set out our Vision 2025, titled Leading with Science, Delivering for Patients, and we described the essential priorities that will support our ongoing expansion and our shift into a commercial entity across the coming five years. Let me restate those priorities, then give a quick look back at what we achieved in 2019, before the team shares additional quarter highlights and news about upcoming developments. The main pillars of Vision 2025 are these. Securing regulatory approvals for a minimum of two medicines coming out of our pipeline. Establishing commercial skills to market and sell our treatments in a way that reflects their novelty and worth. Producing revenues from product sales that keep growing sustainably. Growing our development pipeline twofold, to reach 10 therapeutic programs. Broadening our discovery platform into muscle energetics, growth, and metabolism, and becoming the sort of science-driven organization that people wish to join and collaborate with. During 2019, we moved closer to those targets. Through our work with Amgen, we finished enrollment in GALACTIC-HF and got through the first interim analysis without any alterations to the protocol or how the study was run. Last week came word that after the second interim analysis of GALACTIC-HF, the Data Monitoring Committee once more advised carrying on with the trial unchanged. Top-line results are now anticipated in Q4 of this year, and we're already getting ready for the trial's close and for reporting the final results; alongside Amgen, we're also preparing for possible regulatory submissions that could result in later commercialization. METEORIC-HF, the second phase III clinical trial for omecamtiv mecarbil, likewise began in early 2019, and we anticipate finishing enrollment in this second phase III trial for omecamtiv mecarbil before this year ends. Additionally, through our partnership with Amgen, we launched the phase I study of AMG 594 during 2019, and we look to wrap up the SAD and MAD study before this year is out. During 2019, we and Amgen made plans for possible next steps in this program, sharing the aim of creating a lasting business franchise built on new medicines targeting the pharmacology of cardiac muscle activation. Aside from our partnership with Amgen, in 2019, related to our fully owned, standalone program concentrating on hypertrophic cardiomyopathies. We produced phase I results for CK-274, and got set to launch our phase II clinical study, REDWOOD-HCM, which started signing up patients earlier in the year; on top of that, during 2019 we saw encouraging outcomes from FORTITUDE-ALS, our phase II trial of reldesemtiv in ALS patients, and we talked with regulators, payers, and KOLs to get ready for a possible phase III trial down the road. I'm also glad that our research efforts kept paying off in 2019, and now we're eager to move CK-271, another of our cardiac myosin inhibitors, into phase I during the first half of this year, and to keep up IND-enabling work for CK-601, a next generation fast skeletal muscle troponin activator, which is likewise headed toward clinical research. For Cytokinetics, 2020 is going to be pivotal, since we now anticipate GALACTIC-HF results before the year is out, and we're getting ready for commercial readiness and co-promotion. We also anticipate pushing forward and widening our pipeline so that two additional programs could potentially move into late-stage trials, while one more program might move ahead in earlier-stage trials. I feel enthusiastic about the progress achieved in 2019 as well as what 2020 could bring. With that, I'll hand the call to Fady, who will go into detail about key developments in our cardiovascular programs.
Fady Malik
executiveThank you, Robert. Prior to getting started, I want to officially extend a welcome to Stuart Kupfer, who joins us as the new Chief Medical Officer. Stuart completed his undergraduate studies and received his MD from the University of Florida, then went on to pediatrics training at Yale University and an endocrinology fellowship at the University of North Carolina. His career began in academic medicine at Washington University, and then in 1998 he moved into biopharma, which included time at Takeda Pharmaceuticals, where he worked for 12 years, serving most recently as a Vice President and therapeutic area Head of cardiometabolics. While there, he gained experience in heart failure, thrombosis, hypertension, and diabetes. Stuart has contributed to six CV outcomes trials, with all the extensive planning and logistical detail those require. At Takeda, Stuart worked alongside colleagues in discovery, commercial, regulatory, and medical affairs to shape the strategy for their cardiometabolic portfolio and to carry out that strategy. I'd also like to express my thanks to Andy for 15 years of service as our Chief Medical Officer. Andy is now becoming our first Senior Fellow, Clinical Research and Development, while remaining one of our Senior Vice Presidents. Through the years, Andy has had a major impact on Cytokinetics. On me personally as well, by establishing the benchmark for careful development of clinical protocols, our engagement with the investigator community, the analysis of data coming out of those trials, and then the communication of those findings. Many of you are aware that he is well recognized in the cardiology and neuromuscular communities, which speaks to the breadth of his work over the years. I'm eager to see Andy's ongoing contributions to our missions and plans in the years ahead. He will play an important role in supporting Cytokinetics' shift toward commercialization. Turning to key developments in Q4 and in early 2020, I'll start by discussing the recent publication of the GALACTIC-HF design manuscript in JACC: Heart Failure, and after that I'll review our even more recent announcement about the second and final planned interim analyses of this trial. As laid out in the design publication, the primary end point in GALACTIC-HF is a composite of time to CV death or first heart failure event, whichever comes first. As we've noted previously, statistical powering of the trial rests on a hypothesis concerning the first secondary endpoint, time to CV death. Accumulating 1,590 CV deaths gives 90% power to detect a hazard ratio of 0.8 for CV death. A sample size of 8,000 patients was selected based on the following assumptions: an annualized rate of CV death of 10% in the first year and 7% thereafter, a 24-month enrollment period, total study duration set to 48 months, a three-month treatment lag with a treatment effect hazard ratio of 0.8 thereafter, a 10% annual rate of study drug discontinuation, and 10% of subjects lost to endpoint determination, whether through non-CV death or study discontinuation over the course of the trial. The overall Type 1 error is 0.05 for two-sided testing. If we assume that the rate of experiencing either a heart failure event or CV death is twice the rate of CV death by itself, and that all other assumptions match those used for CV death alone, then for the primary composite endpoint the analysis should carry statistical power above 99%. Now, regarding the second interim analysis, I hope everyone noticed the announcement we made last week: after the second and final planned interim analysis of GALACTIC-HF, the Data Monitoring Committee advised that the phase III clinical trial of omecamtiv mecarbil should keep going, with no modifications to how it is conducted. That second interim analysis was set off when two-thirds of the 1,590 cardiovascular deaths specified in the trial's protocol had been observed in GALACTIC-HF. This second interim analysis incorporated evaluations intended to rule out futility and to allow an earlier halt of the trial should overwhelming efficacy be found, with both decisions left to the DMC's discretion. Through the futility analysis, the DMC could weigh stopping GALACTIC-HF in the event of a low probability that the trial would show a clinically meaningful and statistically significant benefit on the primary endpoint by the trial's end among patients given omecamtiv mecarbil plus standard of care, versus those given placebo plus standard of care. Through the superiority analysis, the DMC could weigh stopping the trial ahead of schedule if the primary composite endpoint along with the first secondary endpoint of CV mortality both reached high statistical significance. Furthermore, it should be noted that the stopping boundaries serve as guidance for the DMC rather than constituting binding rules. When making recommendations about trial conduct, the DMC reviews all evidence available, and other factors might have justified carrying on with GALACTIC-HF even if numerical superiority boundaries had been reached in the planned analysis. As we have said before, seeing GALACTIC-HF continue to full term was the outcome that we and Amgen anticipated most, particularly because the trial was close to reading out at full term as originally planned, with top-line results anticipated later this year. Having the trial finish its full course guarantees the robustness of data on the primary endpoint and every one of the secondary endpoints. Given where the timeline to top-line results from GALACTIC-HF now stands, the teams at Cytokinetics and Amgen have concentrated on regulatory, medical, and commercial readiness activities and have sped up certain work streams so they can prepare for a potentially earlier approval and commercial launch. We also introduced our disease state education campaign at AHA, aimed at teaching healthcare professionals about the part cardiac contractility in the sarcomere plays in heart failure; now that results from GALACTIC-HF are expected in Q4, what does that imply for when METEORIC-HF will read out and for our regulatory filing plans? METEORIC-HF will read out after GALACTIC-HF, and possibly after we file initial regulatory applications for omecamtiv mecarbil, which would rest on GALACTIC-HF. To phrase it differently, the METEORIC-HF trial isn't essential to our filing timeline, and our current expectation is that those data would be handed to regulators at a point following an initial possible marketing application, which positive GALACTIC-HF results would underpin. Turning to look back at Q4, during November we disclosed further findings from COSMIC-HF. That phase II study demonstrated that alongside boosting the heart's pumping action, systolic function, omecamtiv mecarbil produced no change in, and on certain measures aligned with, an improvement in the heart's diastolic function — its capacity to relax between beats. Our view is that this evidence, enhancing the heart's pumping capability while not harming how it fills, adds to the therapeutic justification for omecamtiv mecarbil in heart failure. Regarding AMG 594, the cardiac troponin activator found through a joint research program with Amgen, the phase I study is ongoing, and we anticipate the SAD and MAD study finishing later this year. We have also set up a collaborative working group, with members drawn from Amgen and Cytokinetics plus external KOLs, to weigh the path forward for AMG 594 in heart failure with reduced ejection fraction and possibly in additional patient populations too. Further details on those potential plans for AMG 594 will come on upcoming calls. Shifting now to CK-274, our next-in-class cardiac myosin inhibitor. During Q4, we readied ourselves for launching REDWOOD-HCM.
Fady Malik
executiveSo, just to remind everyone, this trial is randomized, placebo-controlled, double-blind, and dose-finding — a phase II clinical study involving patients who have symptomatic obstructive HCM, or oHCM. What we're primarily trying to accomplish with this trial is establishing how safe and how well tolerated CK-274 is. Then we have secondary objectives, which involve characterizing the concentration response relationship of CK-274 on the resting and post-Valsalva ventricular outflow tract gradient, measured through echocardiography, over the course of 10 weeks of treatment. On top of that, the trial is going to assess plasma concentrations of CK-274 among oHCM patients in relation to dose. When it comes to exploratory objectives, these cover the impact of CK-274 on N-terminal prohormone of brain natriuretic peptide, or NT-proBNP, as well as the New York Heart Association functional classification. Just as a reminder, in our phase I study, CK-274 demonstrated that it hit the pharmacodynamic effect we were aiming for, along with an exposure response relationship, and it got to steady state in 14 days, which is what allows for a dose titration regimen at intervals of two weeks. The way REDWOOD-HCM is set up, we're evaluating a flexible dose optimization schedule for CK-274 — its therapeutic window and the echocardiographic parameters tied to clinical outcomes in HCM patients. Enrollment will happen in two sequential cohorts, with the possibility of adding a third. In each cohort, 18 patients get randomized in a 2: 1 ratio to active treatment or placebo, respectively, and they'll receive as many as three escalating doses of CK-274 or placebo, guided by echocardiography. Following two weeks of treatment at 5 mg once daily, an echocardiogram is performed on patients to figure out whether they'll be up-titrated to the next higher dose, which is 10 mg once daily. Then, after another two weeks of treatment, patients get a second echocardiogram to determine whether they'll be titrated up to 15 mg once daily, which is the top dose in cohort one. As for cohort two, those doses will be decided once we've reviewed the cohort one data. All told, treatment lasts 10 weeks, with an echocardiogram done to confirm reversibility of effect two weeks after the final dose. For REDWOOD-HCM, we expect enrollment across roughly 20 investigative sites located in North America and Europe, and we're happy to say that screening and enrolling of patients is currently underway. We just held our North America investigators meeting for REDWOOD-HCM recently, and it was great to witness the enthusiasm for our next generation approach to cardiac myosin inhibition, which could potentially move clinical research forward when it comes to treating obstructive hypertrophic cardiomyopathy. With REDWOOD-HCM now up and running, we've moved another step closer to potentially having a next-in-class therapy available — one that might optimize treatment of the underlying cause of patient's disease while also relieving the very limiting symptoms that have such a significant impact on overall quality of life for patients with oHCM. We're looking forward to sharing cohort one data in the second half of the year. And also, as part of our cardiac sarcomere inhibitor program, we recently announced that CK-271, a second cardiac myosin inhibitor, is advancing, and we expect it to enter phase I during the first half of 2020. A defining feature of how Cytokinetics carries out research and development is pushing several compounds forward so that a drug development program can potentially grow into additional indications and groups of patients. With CK-271, there may be a chance for us to broaden the clinical development program past obstructive and non-obstructive HCM and look into other possible patient populations that could gain from a cardiac myosin inhibitor. Once translational research moves ahead and we produce data in the clinic, we'll be able to share more on this; at this point I'll hand things to Andy for an update on the fast skeletal muscle activator program we're focused on, reldesemtiv.
Andy Wolff
executiveAppreciate that, Fady. When it comes to reldesemtiv, alongside the talks currently underway with Astellas about a proposed change to the collaboration agreement between us, we're still working with FDA, EMA, and health technology assessment groups to figure out what our possible next steps look like — that includes the clinical and reimbursement value of the endpoints we might use for a pivotal trial under consideration. During Q4, we set up Type C interactions with FDA so we could get input on important questions along with the statistical analyses we had planned. Although additional FDA interactions are still expected, the team is simultaneously pushing to lock down a protocol, timeline, and budget. What we hear from these continuing conversations with outside stakeholders — a lot of them scheduled during the first half of the year — will shape our final approach and the call on how we might move reldesemtiv ahead into a possible phase III clinical trial for patients with ALS. Let me be clear: that call will be made after we see results from GALACTIC-HF in Q4 of 2020. That said, the feedback coming our way is encouraging, and it highlights strong enthusiasm for the mechanism and data behind reldesemtiv and what it could offer in ALS. We're also impressed by the positive input we keep getting from ALS key opinion leaders, who are pushing for us to move forward and are joining us in our planning exercises. Back in December, at the ALS/MND meeting held in Perth, we shared subgroup analyses from FORTITUDE-ALS showing that when all active doses were pooled and compared against placebo, reldesemtiv produced a comparable effect on SVC, ALSFRS-R, and muscle strength measured by handheld dynamometry at 12 weeks, regardless of whether patients were on edaravone and/or riluzole. Most patients were taking riluzole by itself — 56.5% — whereas just 4.2% were on edaravone alone, and 20.6% were on both. As the treatment landscape in ALS keeps changing, these data show how we might potentially further slow disease progression decline by layering new mechanism therapies such as reldesemtiv on top of treatment regimens patients already use. We also shared FORTITUDE-ALS data showing that patients who got reldesemtiv during the trial saw a significant delay before prescription of and agreement to use durable medical equipment, such as manual or power wheelchairs, gastrostomy tubes, non-invasive ventilation, and assistive communication devices; these findings, along with results from FORTITUDE-ALS reported earlier, underscore how robust and consistent the trial data are, which we believe supports advancing reldesemtiv in patients with ALS. Lastly, in December, FDA awarded orphan drug designation to reldesemtiv for treating ALS. That comes after we had obtained orphan drug designations from both FDA and EMA for treating spinal muscular atrophy. With that, I'll hand things over to Robert Wong, who will give an update on our financials.
Robert Wong
executiveThank you, Andy. To begin, I'll walk through where we stand on cash, revenue, and expenditures, after which Ching will go over the 2020 financial guidance and our approach to corporate development. You can find additional information about our actual fourth quarter 2019 results in the press release that went out earlier this afternoon. We closed out the fourth quarter with roughly $268 million in cash and investment. Q4 2019 revenue was generated through our strategic alliances with Amgen and Astellas; on the Amgen side, we recorded revenue tied to their reimbursement of development expenses for METEORIC-HF; with Astellas, we booked revenue for reimbursement of research activities, plus development expenses incurred as we wrapped up FORTITUDE-ALS. R&D expenses for the fourth quarter of 2019 fell to $18.3 million, down from $23.3 million during the same period in 2018, largely driven by reduced spending on neuromuscular development activities, partly offset by greater activity around METEORIC-HF and CK-274. As anticipated, over half of R&D expenses came from our cardiovascular program, reflecting work on METEORIC-HF and the cardiac myosin inhibitor program. The rest of our expenses were mainly tied to early research activities. G&A expenses for Q4 2019 reached $10.6 million, compared with $7.6 million in Q4 2018, mostly because of higher personnel-related costs, including stock-based compensation, along with greater outside services. Ching will now go over the 2020 guidance and discuss our corporate development strategies.
Ching Jaw
executiveAppreciate that, Robert. We came out today with our 2020 financial guidance. Cash revenue, per the company's expectation, should land somewhere between $18 million and $22 million. Operating expenses ought to fall within $120 million to $130 million. Net cash utilization is projected to be between $105 million and $115 million. Given that we closed 2019 holding $268 million in cash, and factoring in this guidance, we headed into 2020 with over 24 months of runway. You'll remember that back in Q4, we brought in $120.5 million, net of underwriter fees as well as capital and other transactional expenses, via a convertible note offering. That convertible note has a 4% coupon rate and a 27.5% convert premium, and it comes due in November 2026. Proceeds are meant to support continued development and commercial readiness work tied to omecamtiv mecarbil. Also the ongoing clinical development of CK-274 and CK-271 for indications linked to hypertrophic cardiomyopathies and related diseases involving diastolic dysfunction and cardiac fibrosis, among them heart failure with preserved ejection fraction. Plus clinical development of reldesemtiv in ALS patients, which includes a possible phase III clinical trial, along with working capital and other general corporate purposes. On top of that, through the quarter we kept chasing project financing and partnership opportunities aimed at broadening development of our cardiac sarcomere inhibitor program and stretching our cash runway further. Both the launch of REDWOOD-HCM and CK-271's progress in development are feeding momentum into those partnering conversations, and we stay hopeful that our broader next-generation cardiac myosin inhibitor program could open the door to additional capital. Beyond that, Cytokinetics qualifies for milestone payments through our Amgen collaboration over the coming years. We're starting 2020 with a solid balance sheet and feel confident about our capacity to deploy capital wisely across prioritized programs so as to maximize shareholder returns. With that said, I'll hand the call back to Robert Blum.
Robert Blum
executiveThanks, Ching. You already heard that the fourth quarter of 2019 was extremely productive for us, and it set us up nicely for what might end up being a genuinely transformative year at Cytokinetics. I'm especially excited about the momentum in our cardiovascular area, given that a second cardiac myosin inhibitor is moving forward and multiple readiness work streams are already in motion to back the possible commercialization of omecamtiv mecarbil. Beyond what Fady laid out, we're also collaborating closely with our Amgen colleagues on launch planning for omecamtiv mecarbil, which might happen in 2021; our pre-launch efforts are being coordinated, and we anticipate finalizing a co-promotion plan that would determine how each company's sales forces are deployed and how their field activities get coordinated afterward. Through the collaboration, we hold commercialization rights for omecamtiv mecarbil in the hospital setting alongside Amgen, and Amgen would reimburse some of our sales force expenses. While we build out and grow our sales organization, we'll aim to refine our go-to-market approaches and upcoming selling efforts by capitalizing on where high-volume heart failure treatment centers overlap with centers of excellence dedicated to treating hypertrophic cardiomyopathies. Also, as we said before, we've started growing our medical scientific liaison team, and we hope to expand that group further during 2020. We've additionally got teams focused on health economics and heart failure outcomes research, building models that will underpin our market access plans and later payer discussions; this year, together with Amgen and alongside academic institutions and healthcare networks, we anticipate producing and publishing key data on the real-world burden of treating heart failure patients, while underscoring the potential for novel therapies to tackle the substantial unmet need and the rising economic burden; to put that in context, the economic burden of treating heart failure patients comes to roughly $31 billion in the U.S. by itself, and that figure is expected to climb past $70 billion by 2030. With heart failure prevalence and burden continuing to rise, we think novel therapies capable of improving clinical outcomes while also easing pressure on healthcare budgets will be embraced enthusiastically by clinicians, administrators, and payers. Now shifting to AMG 594, CK-274, and CK-271, Cytokinetics is substantially broadening and extending where we stand in cardiovascular drug development; we're lucky to be able to draw on more than 15 years of clinical research involving omecamtiv mecarbil to shape trials for these newer candidates and to think through the best ways to build franchise strategies around our programs aimed at cardiac muscle activation and inhibition — approaches that we hope will help more patients and deliver stronger returns. We stay very conscious of the unmet needs that heart failure, HCM, ALS, and SMA patients face right now, and we're still driven to keep executing effectively toward our vision of delivering medicines with novel mechanisms to those patients; at the same time, we must stay disciplined about how we run our operations and keep an eye on our cost of capital. We have to think about the best ways to broaden our access to capital so we can expand our pipeline, while using partnerships to help reach our objective of producing sustainable cash flows; for a long while now, we've viewed omecamtiv mecarbil as a central lever for growing our company, and we're glad that during this calendar year, pivotal trial data from GALACTIC-HF will arrive to best guide our path forward. So we'll use those results to shape our strategies concerning reldesemtiv in ALS; that's the advantage of having built our position as one of the leaders in muscle biology and holding a broad portfolio of promising drug candidates. One program shapes our outlook for the rest, as well as our underlying cost of capital. We'll keep preparing to launch a phase III trial of reldesemtiv; we'll wait for GALACTIC-HF results before possibly beginning that trial; we also anticipate wrapping up ongoing talks with Astellas during this first quarter about amending our collaboration, which should clarify matters involving technology transfer, drug supply, co-funding, royalties, and so on. We're eager to update you on our plans as the year goes on. Let me summarize our expected milestones for 2020; for omecamtiv mecarbil, we anticipate top-line results from GALACTIC-HF in the fourth quarter. We anticipate finishing enrollment in METEORIC-HF among patients with heart failure in 2020. For AMG 594, we anticipate that Amgen will finish the phase I of the SAD and MAD study during the second half of 2020; for CK-274, we anticipate that data from the first cohort of patients enrolled in REDWOOD-HCM will be available during the second half of 2020. For CK-271, we anticipate filing an IND and beginning a phase I study during the first half of 2020. For reldesemtiv, we anticipate engaging with regulatory and reimbursement authorities in 2020 to get ready for a potential phase III clinical trial and registration program among patients with ALS. For our ongoing research, we anticipate continuing research activities aimed at the cardiac and skeletal sarcomere and our other muscle biology research programs, and we anticipate continuing research alongside Astellas aimed at discovering next-generation skeletal muscle activators through 2020, subject to current negotiations. Operator, with that, we can now open up the call, please, to questions. Good afternoon, Jason.
Jason Butler
analystHello, Robert. I appreciate you fielding these questions, and congratulations on everything that has been accomplished. I have a few regarding omecamtiv, followed by one brief item about CK-274. Regarding the powering assumptions Fady presented, could you share your perspective on the potential treatment effect as time goes on? Should we anticipate that it stays steady, or might it rise or fall compared with the first year, when the event rate is expected to be at its peak? My other question concerns reimbursement. Perhaps you could describe your approach for engaging with payers, considering that the Entresto experience involved reimbursement obstacles that turned out greater than anticipated during the initial couple of years it was on the market? Thank you.
Robert Blum
executiveCertainly. Fady will take your initial question, and after that I will handle the second one.
Fady Malik
executiveYes, hello Jason. Regarding your initial question, our position was that during the opening 3 months there would be minimal impact from the treatment. The reasoning behind this is that we begin with a starting dose, and reaching the target dose requires a few weeks, and perhaps a certain amount of time would pass before any benefit builds up. This represents a cautious view, since it heavily influences the powering assumptions. Having said that, I believe that if you examine the majority of outcomes trials and their Kaplan-Meier curves, frequently the benefit starts accumulating quite soon and keeps accumulating throughout the study in a roughly continuous manner. I think we did power the study. The assumptions we used when designing the trial were cautious, and intended to account for the chance that a treatment lag might exist.
Robert Blum
executiveOn your second question, at Amgen we've taken a particularly forward-leaning stance on such matters. For a couple of years now, we've been collaborating on preparations for talks with payers and reimbursement authorities — both to grasp the landscape and to partner with selected healthcare systems so that their data can be mined, letting them better grasp what their present economic burden might be tied to the way heart failure is currently managed. We also hinge on the GALACTIC results. One might anticipate budget savings plus possible pharmacoeconomic upside. I'd call us diligent pupils of the history here, and yes, I do think about your remark about Entresto and the initial difficulties, which in my view they've gotten past. To a great extent, they cleared a route that I believe we may follow in certain ways. Cardiovascular clinics and heart failure hospitals today are far better equipped for newer medicines, largely since they know how to engage reimbursement authorities when weighing new innovations. I think we'll be positioned, having put in substantial investment during this peri-launch period, to collaborate with them. What we hope for is a smoother first launch, particularly when it comes to payers grasping what a new therapy in this space could offer.
Jason Butler
analystExcellent, that's useful information. Thank you, Robert. And then, very briefly, could you draw a comparison between the preclinical PK/PD profiles of CK-271 and CK-274?
Robert Blum
executiveThat topic hasn't come up much in our discussions, and I suspect we'll hold off on addressing it until we've obtained the phase I results, at which point we can go into greater detail regarding our expectations for how CK-271 might move forward alongside CK-274. Obviously, there must be distinctions between these compounds, otherwise CK-271 would never have been progressed. Still, given our desire to ensure that whatever we say is grounded in data, I believe it's preferable to postpone this discussion until the phase I data are available.
Jason Butler
analystAll right, excellent. Appreciate you letting us ask.
Robert Blum
executiveYou're welcome.
Robert Blum
executiveHey, Joe.
Joe Pantginis
analystHello, everybody. Good afternoon. The first thing I want to ask about is GALACTIC-HF, and it's really a logistics-type question. I'm just wondering, when it comes to your talks with Amgen, how are you planning to communicate? Do you happen to know whether the two of you intend to put out word that the final event has been reached, or will we simply receive an announcement about the final data?
Robert Blum
executiveYeah. I wouldn't anticipate that we'd be telling you the point at which that final CV death has been accrued. Instead, what you ought to expect is that the next time we announce something jointly, it will include the top-line results.
Joe Pantginis
analystGreat, that helps. Thank you. This may be a bit of a rhetorical one, but I'm just wondering — given what an enormous, almost Herculean volume of data this involves, how confident are you and Amgen that you can reach the 4Q 2020 data readout and manage to pull together the patient files from 8,200 patients, and so on?
Fady Malik
executiveYeah, no, pulling all of that together is always a Herculean job. I'd say the fourth quarter is our best estimate at this point. There were no coronavirus issues globally, plus all sorts of other factors. I think we're well within the fourth quarter and expect that we'll be able to deliver on it.
Robert Blum
executiveA key point to keep in mind is that when you carry out a second interim analysis as planned, you need to clean the data and bring it forward for what ends up being a substantial share of the data that would also be part of a final analysis. As you might expect, we are already — actually, I shouldn't say we; Amgen and we at Cytokinetics, working together, are already quite far along that road when it comes to the events that have already been accrued, along with gathering and cleaning that data. I genuinely believe Amgen and Cytokinetics have stayed particularly attentive to these timelines, and I think it's fair to expect what we've reported, namely that we anticipate results in Q4.
Joe Pantginis
analystThat's great, thanks. Real quick, regarding CK-274 — sorry, I mean reldesemtiv. Clearly, as you just said, there was a Type C, and from what I understand, you've received considerable feedback from the regulators, plus a good deal of information that I believe has opened the door for you to shape your plans while waiting on the GALACTIC result. So I suppose my question is this: what do you consider still unresolved that you need, let's say from the FDA, in order to lock in a final protocol before GALACTIC data comes out?
Robert Blum
executiveSure. Excellent question. I'll begin, and then perhaps hand it to Andy. Partly, one thing we're trying to make certain of is that we're on the same page among FDA, EMA, and HTAs regarding the optimal way to design and run a phase III trial in a setting where things are shifting, where new therapies are under evaluation and testing, where edaravone has approval in the U.S. but not in Europe, and where, if we proceed, we need to be sure our endpoints genuinely translate into value as judged by reimbursement authorities, particularly in Europe.
Andy Wolff
executiveRight, there isn’t much more for me to say on that. I’d simply stress that feedback coming from various regulators — EMA, FDA, and health technology bodies — doesn’t always align, so you need to ensure you can bring it into harmony as much as you can.
Robert Blum
executiveRight. And I should add as well, since we're transitioning here from what would be the conclusion of phase II into phase III, we want to be certain we grasp everything a registration program demands, not merely a phase III trial. Are there additional clinical pharmacology studies? Are there non-clinical activities that must likewise be planned and carried out so we can clear that threshold? If you're going to run a phase III study, you also want to have the best possible understanding that you're in agreement on the statistical methodologies used to analyze those results. All of that needs to be folded in too. That calls for additional, particular attention and care, along with numerous regulatory interactions with various regulatory authorities across differing jurisdictions.
Joe Pantginis
analystExcellent. That's all quite useful. I really appreciate it, everyone.
Robert Blum
executiveThanks, Joe.
Robert Blum
executiveHey, Chad.
Chad Messer
analystHello there. Good evening. I appreciate you taking my question, and I'm really thrilled to be participating in a quarterly call alongside you, discussing omecamtiv mecarbil data this year. Just mulling over the nice predicament of GALACTIC-HF having read out ahead of schedule — I fully grasp, based on your prepared remarks and what we've talked about previously, that this isn't on the critical path for filing. How significant are the METEORIC-HF data for other purposes, in particular for conversations with payers and your strategy for market access?
Fady Malik
executiveIn my view, the METEORIC data add to what we'll observe in GALACTIC, yet they are not, I'd say, essential to the value proposition that would be put forward for omecamtiv mecarbil. That will truly depend on mortality benefits and rehospitalization benefits. When it comes to symptom relief and exercise, functional improvement, those are matters that clearly matter a great deal to patients and to physicians and assist in driving the rationale behind the use of omecamtiv mecarbil. We do believe the data matter, but their timing isn't necessarily essential for the launch of omecamtiv mecarbil.
Robert Blum
executiveYes, I share Fady's view that the decisive factor for whether omecamtiv mecarbil gets into the guidelines, and for how payers will see it, is whatever GALACTIC ends up showing. Certainly that applies to where it sits against other possible treatments, and it could also shape how well patients stick with and follow their regimen. If METEORIC likewise produces positive results, I believe that would be additive and would help drive some of the uptake we're anticipating in terms of commercial momentum.
Fady Malik
executiveYeah, just to give a bit of context, when you look at other heart failure medications, hardly any of them can show proof of better function through exercise.
Chad Messer
analystAll right, that's useful. Perhaps a brief question regarding AMG 594. As I recall, you stated — and it also appears in your press release — that the phase I SAD and MAD cohorts are set to finish during the second half of 2020. I'm just curious whether those of us in the investment community ought to anticipate getting that data, and if we should, at what point?
Robert Blum
executiveThat's a fair question; 594 has us especially enthusiastic since its pharmacology differs, and it might let us extend a franchise past what we'd accomplish with omecamtiv mecarbil. We could possibly have the SAD and MAD study data before this year ends, though neither we nor Amgen have discussed whether such data would be made available. My guess is that depends heavily on whether more phase I data must be produced and on what our phase II strategy will be. Those matters remain under discussion between Amgen and us. We are deliberately not providing guidance toward data within this year, but instead toward the SAD and MAD study reaching completion.
Chad Messer
analystAll right. Great. Understood. Thank you.
Robert Blum
executiveThank you.
Robert Blum
executiveHello, Charles.
Maria Yonkoski
analystHello, I'm Maria Yonkoski, filling in for Charles. Thanks for fielding the question, and kudos on such a productive year. You did touch on this somewhat while responding to a question earlier, though for additional clarity, what kinds of disruptions might the coronavirus bring about for the global GALACTIC trial, given that you have sites in Asia? Could you remind us whether METEORIC is enrolling solely at U.S. sites? I have a follow-up.
Robert Blum
executiveCertainly.
Fady Malik
executiveThat was partly perhaps a somewhat offhand remark, but clearly the coronavirus is hitting a lot of nations, and not only within Asia. In European countries, you're seeing conferences get called off. There are obviously problems here in the United States as well; that's a matter we have to think about. Still, my view is that I don't expect this to affect how the trial is run or its completion.
Robert Blum
executiveYeah, it's a reasonable thing to ask, but honestly, answering something like that feels too early — for Cytokinetics, and frankly for just about any other company too. It's a topic we're discussing internally, and we're working out the timing around country closeout and the other items that still have to happen. As things stand, we haven't seen anything that would suggest a disruption to our timelines. As for what you asked about METEORIC and the location where that trial is running, right now it's running across the United States, and we'll be adding Europe to that as well. Along those lines, we're also mindful that something like the coronavirus might impact our timelines. Still, based on where enrollment stands at the moment, I'd say we're reasonably confident about hitting the guidance we provided today.
Maria Yonkoski
analystOf course. I appreciate the response. Regarding my follow-up, it concerned Astellas wrapping up its backing of research work by the close of 2019. You noted there are continuing talks set to finish during this quarter, but I wanted to ask whether the financial outlook you gave presumes that from now on you'll assume the entire funding obligation previously held by Astellas?
Ching Jaw
executiveFor 2020, what we've assumed is that Astellas keeps supporting our research FTE under the terms of the agreement. The financial guidance reflects that.
Maria Yonkoski
analystOkay. Thank you so much.
Robert Blum
executiveThank you.
Robert Blum
executiveHi there, Jeff.
Jeff Hung
analystHello. I appreciate you fielding these. Given what Fady said in his prepared comments about taking CSK-271 into development past HCM, should we read that as CK-271 being used only outside of HCM?
Robert Blum
executiveBeing that specific feels premature to me, though obviously, by adding CK-271 into development, we do anticipate the possibility of moving past HCM. That remains to be settled, and it hinges on further translational research we are conducting, more phase I data we expect to produce during 2020, plus whatever happens with our partnering talks and how those ultimately resolve. With CK-271 sitting in clinical development, we gain greater latitude regarding how this program could be advanced, yet committing to the degree your question perhaps suggests would be premature.
Jeff Hung
analystOkay, thank you. How are you viewing omecamtiv mecarbil and AMG 594 in a heart failure space that may be shifting because of SGLT2 inhibitors and vericiguat?
Fady Malik
executiveSo, clearly, in my view, omecamtiv mecarbil is many years ahead of AMG 594. What we learn from GALACTIC is going to shape how AMG 594 gets developed. One can picture AMG 594 being brought forward as a follow-on to omecamtiv mecarbil, with the hope of demonstrating even better efficacy. Naturally, that hinges on what GALACTIC shows us. One can also picture additional forms of heart failure that omecamtiv mecarbil has not covered which could be especially well matched to what AMG 594 can do. I believe there is an opportunity to move the drug ahead both in HFrEF and in other distinct indications where omecamtiv has not yet been able to address.
Robert Blum
executiveOn the second half of what you asked about — SGLT2 inhibitors along with vericiguat — it's a really thrilling period right now for novel heart failure treatments, and my view is that each of them could work in a complementary fashion. There's a saying Andy often uses: because of how we positioned and developed omecamtiv mecarbil, the hope is that it can serve as foundational to standard of care, given that it works directly on cardiac muscle and might directly boost cardiac function and performance. So honestly, it was built to pair with and complement those other mechanism drugs, which likewise carry clear benefit yet bring something distinct to heart failure treatment.
Jeff Hung
analystGreat. Perhaps one final question. Regarding GALACTIC, which variable factors could affect or influence whether the data are more likely to arrive in the early portion of four Q versus the later portion?
Fady Malik
executiveI'm not able to really say anything about that. The event rate clearly is going to decide when the trial concludes, and after that how much time we need to shut sites down and everything of that nature. As was mentioned earlier, it's a hugely complex and Herculean undertaking to deliver a trial across 35 countries worldwide, and I believe it's far too soon to say with precision precisely when it will come in.
Jeff Hung
analystGreat. Thanks.
Robert Blum
executiveThank you, Jeff.
Robert Blum
executiveGood afternoon, Ted.
Edward Tenthoff
analystHey, everyone. Congratulations on all those fantastic updates. This is going to be a truly thrilling year. Two questions, if I could. First, just a small bit of housekeeping. I want to confirm I heard this right. What was the amount of gross proceeds that got taken down on the convert? Second, since you're looking toward and anticipating and hoping for positive data from GALACTIC-HF, what steps are being taken regarding commercialization prep, and what would Cytokinetics' expense requirements be? Thanks so much.
Robert Blum
executiveFirst, we'll turn to your initial question about the gross proceeds in the convert deal.
Ching Jaw
executiveTed, it’s Ching. The convertible transaction brought in $138 million in gross proceeds, and once we subtract the transaction fees and the costs associated with the cap call, the net amount comes to $120.5 million.
Edward Tenthoff
analystGot it. That's great, thanks.
Robert Blum
executiveIf I understand you correctly, you're asking for a bit more detail about the specific work we're doing alongside Amgen. What I'd say is that we're particularly happy that Amgen and Cytokinetics are collaborating so well across a wide range of work streams. Our joint commercial operating teams work hand in hand with joint commercial committees, which in turn work hand in hand with joint development committees, all of which report up to a joint steering committee. Every one of those committees has its own charter and its own work streams. There are honestly hundreds of activities taking place between the two companies, all in close coordination. At Cytokinetics, we obviously can't match Amgen person for person, but our functional team leaders work hand in hand with their opposite numbers at Amgen. Some activities Cytokinetics carries out, and others Amgen handles. Since we're now in what you might call launch readiness mode, we're reviewing launch preparation plans on a region-by-region basis, and we're conducting market research and working hand in hand on items as varied as choosing brand names and disease state education, positioning, logos, icons, and color schemes. As I said earlier, we're discussing health economics and outcomes research; we're working hand in hand with Amgen, including when it comes to targeting key accounts and whether that ultimately calls for Amgen personnel, Cytokinetics personnel, or both. I'd say this is far more than I could reasonably cover on an earnings call such as this. It's enough to say that we've had plenty of time to prepare for the possible commercialization of omecamtiv mecarbil. We've had plenty of time to consider what must be done to be proactive, and I believe we and Amgen are doing a very good job getting ready for what could be a major opportunity for a new medicine in this disease area.
Edward Tenthoff
analystThat's great, and I'm glad to hear where things stand. Thanks for that.
Robert Blum
executiveAppreciate it, Ted.
Robert Blum
executiveI'd like to express my appreciation to everyone who joined the teleconference today, for both your ongoing backing and your ongoing attention to Cytokinetics. We've described what amounted to a quite strong 2019 in terms of delivering on our goals and objectives and preparing our Vision 2025 and the crucial place 2020 holds in that effort; we're eager for what 2020 may bring, which could be significant milestones with the potential to transform our company and also our mission related to pushing our science forward for the possible good of patients; we're excited to keep you informed, and with that, operator, we can wrap up the call.
Operator
operatorThank you, everyone, for joining us. That brings us to the end of today's conference call. You're welcome to disconnect at this time.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Cytokinetics, Incorporated transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Cytokinetics, Incorporated earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Cytokinetics, Incorporated or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.